16 December 2022 in Science Advances
Direct cardiac reprogramming has emerged as a promising therapeutic approach for cardiac regeneration. Full chemical reprogramming with small molecules to generate cardiomyocytes may be more amenable than genetic reprogramming for clinical applications as it avoids safety concerns associated with genetic manipulations. However, challenges remain regarding low conversion efficiency and incomplete cardiomyocyte maturation. Furthermore, the therapeutic potential of chemically induced cardiomyocytes (CiCMs) has not been investigated. Here, we report that a three-dimensional microenvironment reconstituted with decellularized heart extracellular matrix can enhance chemical reprogramming and cardiac maturation of fibroblasts to cardiomyocytes. The resultant CiCMs exhibit elevated cardiac marker expression, sarcomeric organization, and improved electrophysiological features and drug responses. We investigated the therapeutic potential of CiCMs reprogrammed in three-dimensional heart extracellular matrix in a rat model of myocardial infarction. Our platform can facilitate the use of CiCMs for regenerative medicine, disease modeling, and drug screening.
9 October 2026 in SSRN Electronic Journal
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
13 August 2026 in Biomaterials